Health Trials

A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

ConditionSevere Asthma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorKinaset Therapeutics Inc

About this trial

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Frevecitinib
  • Placebo

Treatment groups

512 Participants
are divided into 4 treatment groups

Locations

15
California
Research site93534, Lancaster United States
Research site95117, San Jose United States
Florida
Research site33511, Brandon United States
Research site33137, Miami United States

Sponsors and collaborators

Kinaset Therapeutics Inc

Lead sponsor

Source ClinicalTrials.gov